Meissa Vaccines
Meissa Vaccines is dedicated to developing innovative vaccines, including intranasal COVID-19 and RSV vaccines, with a focus on safety, immunogenicity, and advancing vaccine technology through clinical trials and manufacturing agreements.
Industries
Nr. of Employees
small (1-50)
Meissa Vaccines
San Francisco, California, United States, North America
Products
Intranasal live-attenuated COVID-19 vaccine candidate
A vaccine candidate designed for intranasal administration using a live-attenuated virus platform, evaluated in preclinical and early clinical studies for safety and immunogenicity.
Intranasal live-attenuated RSV vaccine candidate (pediatric program)
A live-attenuated vaccine candidate formulated for intranasal delivery with a pediatric clinical development path, advanced to Phase 2 dosing and supported by cGMP manufacturing arrangements.
Multivalent human rhinovirus vaccine program
A development program aimed at creating a multivalent vaccine against human rhinoviruses, supported by government SBIR funding.
Intranasal live-attenuated COVID-19 vaccine candidate
A vaccine candidate designed for intranasal administration using a live-attenuated virus platform, evaluated in preclinical and early clinical studies for safety and immunogenicity.
Intranasal live-attenuated RSV vaccine candidate (pediatric program)
A live-attenuated vaccine candidate formulated for intranasal delivery with a pediatric clinical development path, advanced to Phase 2 dosing and supported by cGMP manufacturing arrangements.
Multivalent human rhinovirus vaccine program
A development program aimed at creating a multivalent vaccine against human rhinoviruses, supported by government SBIR funding.
Services
cGMP manufacturing partnership facilitation
Establishing agreements with contract manufacturers to produce clinical-grade vaccine material for pediatric and clinical programs.
Clinical trial initiation and management support (Phase I/II)
Support for initiating early-stage clinical studies including first dosing and management of safety/immunogenicity data collection.
Preclinical development and animal model testing
Design and execution of preclinical studies in animal models, including non-human primates, for vaccine candidate evaluation.
Grant-supported translational research management
Management and execution of R&D projects supported by government grants, including SBIR-funded programs.
cGMP manufacturing partnership facilitation
Establishing agreements with contract manufacturers to produce clinical-grade vaccine material for pediatric and clinical programs.
Clinical trial initiation and management support (Phase I/II)
Support for initiating early-stage clinical studies including first dosing and management of safety/immunogenicity data collection.
Preclinical development and animal model testing
Design and execution of preclinical studies in animal models, including non-human primates, for vaccine candidate evaluation.
Grant-supported translational research management
Management and execution of R&D projects supported by government grants, including SBIR-funded programs.
Expertise Areas
- Vaccine R&D for respiratory viruses
- Intranasal vaccine development
- Preclinical infectious disease modeling (non-human primates)
- Early-stage clinical trial management (Phase I/II)
Key Technologies
- Live-attenuated vaccine platforms
- Intranasal delivery formulations
- Non-human primate efficacy models
- Phase I/II clinical trial conduct